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Genetic susceptibility to severe course of nephropathia epidemica
caused by Puumala hantavirus. Nephropathia epidemica (NE) caused by
Puumala hantavirus is one type of hemorrhagic fever with renal syndrome
(HFRS). There is considerable variability in the clinical severity of NE.
Many infections are subclinical but the disease can even be fatal. We
questioned whether the wide spectrum in the outcome of NE is dependent
on host-related immunological factors by determining the major histocom-
patibility complex markers (MHC) in 74 adult patients with NE. Patients
with the most severe course of the disease had a very high frequency of
HLA B8, C4A*Q0, and DRB1*0301 alleles. HLA B8 was found in all 7
(100%) patients with shock and in 9 of the 13 (69%) patients who required
dialysis, versus in only 25 of 74 (34%) in the entire population, and in 14
of 93 (15%) controls. In addition, various other clinical findings pointing
to a severe form of NE were found to be associated with these alleles.
Interestingly, the same MHC alleles are risk factors for various autoim-
mune diseases. This is the first study where a certain HLA haplotype is
found to be associated with the clinical course of an acute viral disease or
acute nephritis.
Nephropathia epidemica (NE), often referred to as a mild form
of HFRS, is endemic in Scandinavia, European Russia and in
Balkans [1]. About 1000 serological diagnoses of NE are made
annually in Finland [21. As judged from the seroprevalence in
Finland (6%), many infections are subclinical or undiagnosed.
During recent years hundreds of Puumala hantavirus infections
have also been reported in Western Europe [31.
The causative agent, Puumala virus, is a member of the
Hantavirus genus in the Bunyaviridae family. HFRS is caused by
several hantavirus serotypes, Hantaan (Korean hemorrhagic fe-
ver), Seoul and Dobrava (or Belgrade) virus [1, 1 The recently
described hantavirus, named Sin Nombre virus, mainly causes
pulmonary symptoms and is lethal in 55% of patients [5, 61. The
natural hosts of hantaviruses are chronically, but asymptomati-
cally infected rodents and insectivores, which transmit the virus to
humans in their excretions. Transmission from human to human
has not been reported. Puumala virus is carried by the bank vole,
Clethrionomys glareolus [7].
NE is clinically characterized by high fever, headache, abdom-
ma! pains and hemorrhages [8, 9]. Hypotension is present in 10%
of patients [8]. The mortality rate is very low, but a number of
lethal cases have recently been reported [10, 11]. The renal
involvement results in transient massive proteinuria, hematuria
and impairment of renal function [12]. Acute renal failure is
present in most hospital-treated patients and transient hemodial-
ysis in needed in a minority [8]. Acute tubulointerstitial nephritis
is the typical renal biopsy finding [12—14]. Common laboratory
findings are leukocytosis, thrombocytopenia, hypoproteinemia
and moderate elevation of liver enzymes, ESR and CRP level.
Increased hematocrit (hemoconcentration) is usual on admission
and is followed by anemia [8, 9].
The pathogenesis of NE is poorly known. Puumala virus causes
no cytopathic effects in cultured cells but has a wide cell suscep-
tibility in vitro [15]. The main site of the virus replication in man
is not known, but endothelial cells are probable targets. In
hantavirus infections, a viral antigen and/or genome has been
detected in the endothelium of many tissues. An important
feature in hantavirus infections is universally increased capillary
permeability [16]. Some NE patients have abnormalities in chest
roentgenography due to pulmonary capillary leakage and acute
renal failure [8]. This feature bears a similarity to the hantavirus
pulmonary syndrome recently described in the United States [6].
It has been suggested that immunological factors are involved
in the pathogenesis of hantavirus infections. The T-cell-mediated
immune response against acute Hantaan virus infection seems to
be important in nude mice [17]. However, increased amounts of
CD8-positive T-cells, mainly killer cells, have also been detected
during the acute phase of the disease in humans [181. Little
information is available on cell-mediated immune responses in
Puumala virus infection.
As persons having certain HLA haplotypes, especially HLA B8
DR3, are known to have an increased or altered immune respon-
siveness to a variety of antigens [19], we sought to establish
whether the tendency to NE, or to some particular symptoms or
findings of NE, is determined by these genetic markers.
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The subjects involved were all treated at Tampere University
Hospital. The material included 51 males and 23 females, aged
from 20 to 75 (mean 43) years. The following previous diseases
were noted: essential hypertension in 12, coronary heart disease in
3, type-2 diabetes mellitus and bronchial asthma in 2 each, as well
217
218 Mustonen et al: Genetic susceptibility to nephropathia epidemica
Table 1. HLA and complement C4 alleles in seven NE patients
suffering from shock
HLA A HLA B C4A C4B DRB1 DQA1 DQBI
2,25 8,15 3 1 0301,08 0401,0501 0201,04
3,9 7,8 nd nd 0301,13 0103,0501 0201,0603
1,3 8,15 3 1,1 0301,13 0103,0501 0201,0603
2 5,8 QO 1,1 0301,15 0101/2,0501 0201,0602
1,28 8 3,00 1,2 0301,01 0501,0101/2 0201,0501
1,3 8 00 1 0301 0501 0201
1 8,15 3,Q0 1 0301,13 0501,0101/2 0201
not determined since no fresh serum sample was available
as multiple sclerosis, psychosis, thyroid papillary carcinoma, rheu-
matoid arthritis and hyperlipidemia in 1 each. Fifty-four (73%)
patients had no chronic diseases. Laboratory values were available
for all patients except serum complement levels that were mea-
sured in 30 patients.
A recent Puumala virus infection was demonstrated in all cases
by a fourfold or greater rise in antibody titer against the virus
(indirect immunofluorescence antibody test) and/or detection of
low avidity of the lgG antibodies to Puumala virus [21.
HLA specimens were gathered in two groups. Samples from
randomly selected 49 patients who had been treated for NE in our
hospital during years 1985 to 1993 were obtained retrospectively
(group A). Another group consisted of 25 consecutive patients
with NE during years 1994 to 1995 (group B).
HLA A, B, and Cw alleles were determined by the standard
microlymphocytotoxicity test. The DRB1 alleles were determined
using group-specific DNA-amplification followed by restriction
enzyme digestions [201. The DQA1 alleles were determined using
the PCR-AFLP method of Ota, Seki and Nomura [211. No
distinction could be made between DQA1*0101 and DQAI*0102;
thus they were typed as DQA*010l/2. For DQB1 typing, a set of
oligonucleotide probes was hybridized to amplified DNA samples
as described elsewhere [221. The validity of the HLA typing results
is constantly monitored by participation in the serological and
DNA-level reference typings organized by the UCLA tissue
typing laboratory. The complement component C4 allotypes were
determined essentially as described by Awdeh and Alper [23].
A control group for HLA studies comprised of 93 cadaveric
kidney donors. The prevalence of Puumala virus antibodies in this
group is not known. The HLA frequencies in our control group
(details not shown) did not significantly deviate from those
reported earlier in the Finnish population [24].
The results are presented as group means and proportions. In
view of the non-normal distribution of variables the differences
between group means were tested by Mann-Whitney U-test.
Fisher's exact test was used for the 2 X 2 tables. The significance
of differences in the HLA allele frequencies was also estimated by
Fisher's exact test. The P values were corrected by multiplying by
the number of alleles tested in each locus.
Results
Serological HLA A, B, and Cw, PCR-typed DRB1, DQA1,
DQB1 and DPB1 alleles, as well as the HLA-linked complement
component C4 allotypes were determined in 74 patients with
hospital-treated NE and their frequencies compared with those in
the control group. None of the differences in allele frequencies
(data not shown) remained statistically significant after correction
Table 2. HLA and complement C4 alleles in 13 NE patients who
required dialysis treatment; the first four patients also suffered from
shock
HLA A HLA B C4A C4B DRB1 DQA1 DQB1
2,25 8,15 3 1 0301,08 0401,0501 0201,04
3,9 7,8 nda nda 0301,13 0103,0501 0201,0603
1,3 8,15 3 1,1 0301,13 0103,0501 0201,0603
2 5,8 00 1,1 0301,15 0101/2,0501 0201,0602
1,2 8 00 1 0301 0501 0201
1,24 8,40 00 1,2 0301,13 0101/2,0501 0201,0604
1,3 7,8 3 1,1 0301,15 0101/2,0501 0602,0201
2,28 8,44 3 1 0301,11 0501 0301,0201
1,3 8,35 nd* nda 01,13 0101/2,0103 0501,0603
2,24 51,44 3,3 1,00 04,09 03 0302,0303
3 18,35 3,3 1,00 04 03 0302
3 18,35 3 1,00 01,13 0101/2,0103 0501,0603
24,28 35,39 nd nd" 14,08 0101/2,0401 0402,0503
nd, not determined since no fresh serum sample was available
(that is, multiplying the P values by the number of alleles
compared in each locus), suggesting that the patient group as a
whole showed no strong HLA association. It was, however, of
interest that slightly higher frequencies of HLA Al (28% vs. 16%,
'uncorr = 0.04), B8 (34% vs. 15%, Pu,,corr = 0.01), and
DQBI *0201 (43% vs. 23%, UnCorr = 0.02) were found in the
patient than in the control group. The frequencies of HLA alleles
were similar in patient groups A and B; for example, HLA B8 was
found in 16 of 49 (33%) in group A and in 9 of 25 (36%) in group
B.
Seven (5 males and 2 females) out of 74 patients were in a
clinical shock on admission. The lowest blood pressure in these
patients was 80/50, 80/40, 78/58, 70/50, 70/40, 60/40 mm Hg and
unmeasurable in one patient. Table 1 shows the HLA alleles in
these patients. It is of interest that they all had the HLA B8,
DRB1*0301, DQA1*0501, DQB1*0201 alleles. None of the re-
maining 67 patients had clinical symptoms of hypotension, and the
lowest blood pressure measured in them was 90/60 mm Hg.
Table 2 shows HLA alleles in those 13 (9 males and 4 females)
who during hospital care required dialysis treatment. Nine (69%)
of these patients were HLA B8 positive and 8 (62%) DRB1*0301
positive. Thus all but one of the HLA B8 positive patients in these
two subgroups (Table 1 and 2) had the HLA DRB1*0301,
DQA1*0501, DQBI*0201 alleles known to be in a strong linkage
disequilibrium with HLA B8 [23]. They apparently also carried
the C4A'null' allele (C4A*Q0), as can be expected [25] from its
strong association with the HLA B8 DRB1*0301 haplotype,
although the C4 phenotyping was not informative in all cases. It is
thus evident that patients suffering from the most severe outcome
of NE frequently carry HLA B8, C4A*Q0, DRB1*0301,
DQA1*0501, and DQB1*0201 haplotypes.
There were no differences in the frequency of previous diseases
between the shock and dialysis groups and the other patients. Of
the patients with clinical shock two had essential hypertension, the
other five having previously been in good health. Three of the 13
who were dialyzed had essential hypertension, the other had no
previous diseases. The age of the patients in these two subgroups
did not differ from that of other patients.
To further study the relevance of this HLA association, a
variety of clinical and laboratory findings were evaluated with
respect to the HLA B8 and DRB1*0301 positivity (Table 3). A
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Table 3. Laboratoly findings in HLA B8 and DRB1*0301 positive and negative patients
Finding
HLA B8 HLA DRB1*0301
Positive
(N = 25)
Negative(N = 49) P value
Positive
(N = 22)
Negative(N = 52) P value
Creatinine-max pinol/liter
Urea-max mmol/liter
Blood leukocyte count-max
(X 109/liter)
Hematocrit-min
Hematocrit-max
Platelet count-mm
(X 109/liter)
Serum protein-mm g/liter
Serum C3 glliter
Serum C4 g/liter
639 (409)
33.0 (17.2)
18.8 (11.9)
0.33 (0.06)
0.47 (0.11)
66 (71)
55 (7)
0.89 (0.20)
0.13 (0.05)
319 (278)
17.7 (12.7)
10.3 (3.6)
0.37 (0.05)
0.43 (0.05)
90 (59)
58 (5)
LOS (0.20)
0.20 (0.06)
<0.001
<0.001
<0.0001
<0.01
NS
<0.01
NS
NS
<0.01
673 (392)
32.8 (16.8)
18.8 (12.3)
0.33 (0.06)
0.47 (0.11)
61(50)
55 (7)
0.94 (0.16)
0.14 (0.06)
323 (290)
18.8 (14.1)
10.8 (4.5)
0.37 (0.05)
0.43 (0.05)
92 (67)
58 (6)
1.02 (0.25)
0.19 (0.07)
<0.0001
<0.01
<0.001
<0.01
NS
<0.05
NS
NS
<0.05
Values are expressed as means (± SD). Abbreviations are: max, maximum; mm, minimum. Statistical analysis is by the Mann-Whitney U-test.
Table 4. Clinical and radiologic findings in HLA B8 and DRBI * 0301 positive and negative NE patients
HLA B8 HLA DRB1*0301
Positive Negative Positive Negative
Finding (N = 25) (N = 49) P value (N = 22) (N = 52) P value
Age years
Lowest systolic BP" mm Hg
Lowest diastolic BP" mm Hg
45(10)
105 (27)
66 (15)
42(12)
121 (15)
75 (11)
NSb
<OOl'
<005b
44(8)
102 (26)
66 (16)
43(13)
121 (15)
75 (11)
NSb
<001b
<0.05"
Shock % 28 0 <0.0001" 32 0 <0.0001"
Abnormal chest roentgenography %
Treatment time at hospital days
45
14 (9)
15
9 (4)
<0.05"
<0.01"
45
13 (9)
16
9 (5)
<0.05"
<0.05"
Values are expressed as means (± SD) and percentages.
a BP, blood pressure
b Mann-Whitney U-test
C Fisher's exact test
total of 25 of 74 patients were positive for HLA B8 and 22/74 for
HLA DRB1*03O1. All DRB1*0301 positive patients also had the
HLA B8 antigen. The data shown in Table 3 clearly indicate that
findings pointing to clinically severe NE were in most cases
strongly associated with HLA B8 and DRBI *0301. The result was
basically similar whether comparison was made with respect to
HLA B8 positivity among the patients, or with respect to
DRI*03O1. Therefore, our data provide no information as to
which part of this haplotype might show the strongest association.
No comparisons with other HLA alleles were done. The highest
serum creatinine and urea values among HLA B8 positives were
602 (435) .tmol/liter and 34.4 (20.6) mmol/liter in group A and
702 (372) mol/liter and 31.1 (12.3) mmol/liter in group B. The
respective values among HLA B8 negatives were 334 (305)
j.mol/liter and 17.6 (13.3) mmol/Iiter in group A and 298 (220)
jmol/liter and 17.9 (12.1) mmol/liter in group B.
Acute renal failure considered severe (maximal serum creati-
nine > 500 .tmol/liter) was present in 15 (60%) HLA B8 positive
and in 7 (14%) HLA B8 negative patients (P < 0.001). All HLA
B8 positive patients had impairment of renal function (maximal
creatinine > 110 ,iimol/liter), whereas in 8 (16%) of the HLA B8
negatives serum creatinine remained normal throughout hospital-
ization (P < 0.0001).
No differences were observed between HLA B8 and
DRB1*O301 positive and negative groups in the highest values of
CRP, ESR, alanine aminotransferase, daily urine protein excre-
tion or the amount of hematuria.
The mean values of lowest systolic and diastolic blood pressure
observed during hospital care were lower in HLA B8 and
DRB1*0301 positive than negative patients (Table 4). About
one-third of HLA B8 and DRB1 *03O1.positive patients suffered
from shock whereas and no one without these HLA antigens had
this clinical expression (Table 4). Shock was diagnosed in four
patients within group A and in three within group B.
Chest roentgenography was taken during hospital care in 63
patients. In 16 (25%) of them abnormalities were observed. These
included pleural effusions, parenchymal infiltrations or frank
pulmonary edema 8]. Altogether 10 of 22 (45%) HLA B8 and 9
of 20 (45%) DRB1 *0301 positive patients had abnormal findings
in chest roentenography (Table 4). Pulmonary edema was found
in three patients, of whom two were HLA B8 positive.
The time the patients were treated at hospital reflects the
clinical severity of the disease. This time was significantly longer in
HLA B8 and DRB1*0301 positive than in negative patients
(Table 4). The average treatment time in patient group B was 13
days in HLA B8 positives and eight days in HLA B8 negatives. All
patients recovered.
The frequency of previous diseases did not differ with respect to
the HLA status (HLA B8 or HLA DRB1*0301) of the patients.
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Seventy-two percent of the HLA B8 positive and 77% of the HLA
DRB1*0301 positive patients had no chronic diseases.
Discussion
The present study reveals that individuals with the HLA B8,
C4A*Q0, DRBI*0301, DQA1*0501, DQB1*0201 haplotype have
a genetic risk of a severe outcome of Puumala hantavirus-induced
nephropathia epidemica (NE). In particular, all patients who
suffered from shock had HLA B8 and DRB1*0301. Also, a more
severe renal failure was associated with these alleles. Our finding
was not explained by a higher frequency of previous diseases in
HLA B8 DR*0301 positive patients. We therefore assume that
this haplotype is a genuine genetic risk factor. As the HLA B8
DR*0301 haplotype is strongly associated with an abnormal
immune response (see below), our results most probably imply
that the immune system of the host is involved in the pathogenesis
of Puumala virus infection.
The HLA B8 DRB1*0301 haplotype is of special interest in
many ways. First, there is a very high linkage disequilibrium
between the alleles of this haplotype [25] and the whole HLA
region encompassing over 3 Mbp of DNA, inherited usually as a
fixed combination. This renders the precise mapping of suscepti-
bility genes within this haplotype difficult, in particular as more
than 50 genes have been identified within this segment [26].
Second, the HLA B8 DRB1*0301 haplotype is very strongly
associated with many autoimmune diseases, among them systemic
lupus, coeliac disease, thyroiditis, Addison's disease, type-i dia-
betes mellitus and chronic active hepatitis [27]. Third, carriers of
this haplotype are known to evince abnormal in vitro responses in
various immune assays; for example, they have defects in immune
complex clearance and hyperresponsivity in mixed lymphocyte
reaction [28]. They also show increased antibody production and
decreased suppressor-cell function [29, 301.
The mechanism connecting this HLA haplotype to these find-
ings or to a particular clinical course of NE is unknown. There are
no obvious explanations for the wide variation in the severity of
renal failure in NE. It does not correlate with the age or the
degree of hypotension of the patients [8, 12]. A predominant
feature of NE is renal damage, that is, morphologically acute
tubulointerstitial nephritis, where tubular epithelial and luminal
changes are accompanied by interstitial edema and inflammatory
cell infiltrates. The cell infiltrates are predominated by lympho-
cytes and also include monocytes/macrophages, plasma cells and
eosinophilic granulocytes [12—14]. Recently a direct invasion of
renal tubules by Hantaan virus was reported [31]. Obviously the
virus infection alone cannot explain the tissue injury in NE, since
in tissue culture Puumala virus will cause no cytopathic changes
[15]. It is therefore conceivable that the immune system of the
host may play an important role in the damage. In principle, the
host's immune response may be related to a direct killing of
infected cells, or there may be an autoimmune-type of response
where the originally virus-targeted immunity attacks against cross-
reacting self structures [321. The autoimmunity mechanism is of
particular interest since the HLA B8 DRB1*0301 haplotype is
strongly associated with autoimmune diseases. Both mechanisms
may also function. In the present study HLA B8 and DRB1*0301
positive patients had marked leukocytosis, possibly reflecting an
altered immune response.
As the HLA B8, DRB1*0301 haplotype invariably carries a
deletion of the C4A gene encoding the C4A component of the
complement system [25], one might conceivably attribute signifi-
cance to the the C4A defect. Defects in the components of the
classical pathway have been associated with impaired clearance of
immune complexes [33], that certainly may be a crucial factor in
certain forms of renal damage. Also, complement activation can
be associated with the pathogenesis of vascular dysfunction [16].
Current data on complement activation in NE, however, is
limited, but low C4 levels could be observed in HLA B8 and
DRB1*0301 positive patients during the acute phase of the
disease. Whether these were acquired or genetically determined
will require further studies.
Some earlier studies indicate that carriers of HLA B8
DRB1*0301 haplotype would have an altered immunity against
viruses. This haplotype, particularly in a homozygous form, causes
failure of the response against hepatitis B vaccine [34, 35]. In
addition, the same HLA alleles have been found to be associated
with a progression to symptomatic AIDS after HIV infection [361.
The present report indicates that individuals with HLA B8
DRB1 *0301 haplotype have an increased risk for severe clinical
course of Puumala hantavirus infection. It is thus possible that
carriers of the HLA B8 DRB1*0301 haplotype are in some
respect more prone to defects in the handling of many virus
infections.
In conclusion, HLA B8 and DRB1*0301 alleles are associated
with a severe clinical course of NE, Puumala hantavirus-induced
HFRS. The pathogenetic mechanism underlying this relationship
calls for further investigation. This is the first study where a
certain HLA haplotype is found to be associated with the clinical
picture of an acute viral disease or acute nephritis. Interestingly,
the same HLA haplotype is known to be associated with several
chronic autoimmune diseases. The authors are of the opinion that
HLA studies should also be undertaken of more severe forms of
hantavirus diseases such as Korean hemorrhagic fever [1] and
hantavirus pulmonary syndrome recently found in the United
States [5, 6].
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